Golidocitinib for fast-worsening lung disease
Part of Lungs & breathing clinical trials.
This trial tests if golidocitinib, a type of JAK inhibitor, can help people with rapidly progressive interstitial lung disease (RP-ILD) — where breathing gets much worse within a month. It's for those who need steroids and other immune-suppressing drugs but haven't tried a JAK inhibitor before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your lung disease has worsened quickly in the last month with new or worse spots on a CT scan, and you have low oxygen levels or a clear drop in lung function.
- You have not taken a JAK inhibitor before.
- You are not on a ventilator or ECMO, and your oxygen needs are not extremely high.
- You are willing to come for regular follow-up visits and lung function tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral JAK1 inhibitor called golidocitnib for people with T/NK-cell lymphoma that came back after treatment or didn't respond. The drug works by blocking a signal that helps cancer cells grow.
This trial tests a combination of golidocitinib (a targeted pill) and a PD-1 inhibitor (a type of immunotherapy) as a maintenance treatment after initial chemotherapy. It may help keep your lung cancer from growing longer.
This trial tests the drug Golidocitinib (a JAK inhibitor) in adults with primary immune thrombocytopenia (ITP) that has not responded well to standard treatments. The goal is to see if it can safely raise and stabilize platelet counts.
This trial tests a combination of two drugs—golidocitinib (a targeted pill) and sintilimab (an immunotherapy)—for people with advanced non-small cell lung cancer that has a high PD-L1 protein level. It may offer a new option if you haven't had immunotherapy before.
This trial tests whether a new class of drugs called JAK inhibitors (which block inflammation signals) is better than a standard treatment (calcineurin inhibitors) for people with lung scarring (interstitial lung disease) caused by Anti-Synthetase Syndrome. It is for people who have not yet taken any immune-suppressing medications for this condition.
This trial tests a drug called golidocitinib for people with advanced lung cancer who developed serious, hard-to-treat blood-related side effects (like low white blood cells, low platelets, or anemia) from immunotherapy. The goal is to see if golidocitinib can help reverse these side effects without stopping cancer treatment.
Hear when a new Interstitial Lung Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.